• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

Social Security's 2032 deadline puts a 22% cut on the table — but Washington has way less room to negotiate than 1983

2

CEO of $20 billion AI firm Perplexity says the secret to success is ‘sleeping with that fear’ that your competitor will steal your idea

3

Iran proved it can close the Strait of Hormuz, but the U.S. is advertising very loudly that the world's top superpower can at least punch open a hole

1

Social Security's 2032 deadline puts a 22% cut on the table — but Washington has way less room to negotiate than 1983

2

CEO of $20 billion AI firm Perplexity says the secret to success is ‘sleeping with that fear’ that your competitor will steal your idea

3

Iran proved it can close the Strait of Hormuz, but the U.S. is advertising very loudly that the world's top superpower can at least punch open a hole
HealthBrainstorm Health

Brainstorm Health Daily: August 7, 2017

By
Clifton Leaf
Clifton Leaf
and
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Clifton Leaf
Clifton Leaf
and
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
August 7, 2017, 1:31 PM ET
Add Fortune on Google for similar content.

Greetings and a happy Monday, readers! This is Sy.

America’s prescription painkiller and heroin addiction epidemic has devolved into a crisis that public health officials, industry leaders, and politicians alike are taking seriously. The latest example? The Drug Enforcement Administration (DEA) is recommending a 20% cut to the manufacturing of certain opioid painkillers and other addictive drugs.

A recent White House-commissioned report on the opioid overdose epidemic recommended a federal “state of emergency” over painkiller abuse and related deaths. “With approximately 142 Americans dying every day, America is enduring a death toll equal to September 11th every three weeks,” the commission noted.

The latest proposal from the DEA proposes that “production quotas for Schedule I and II substances reflect the amount needed to meet the United States’ medical, scientific, industrial, export and reserve requirements”—and nothing more.

Read on for the day’s news.

Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

DIGITAL HEALTH

The smartphone has ensnared Generation Z. My colleague David Morris highlights social psychologist Jean Twenge's sobering findings about social culture and social media among Generation Z (that's the one after us much-derided "Millennials"). "Today’s twelfth graders spend less time out of the house without their parents than eighth graders did in 2009. Only 56% of high school seniors dated in 2015, compared to 85% for Gen Xers and Baby Boomers. The number of teens who spend daily time with friends dropped by 40% between 2000 and 2015," David writes. One possible reason for this paradigm shift? Technology. Cyberbullying and depression rate spikes can go hand-in-hand; but there are also obvious advantages to increased information access facilitated by technology, such as drops in teen pregnancy. (Fortune)

An expansion of telehealth services for veterans. The Trump administration is rolling out a new initiative to expand telehealth services to veterans, including by promoting such technologies within the Department of Veterans Affairs. "The same technology that the president of the United States has access to we're bringing to our veterans," said VA Secretary David Shulkin about the VA Video Connect mobile app which can reportedly connect veterans with doctors practicing across 50 different specialties.

INDICATIONS

Zynerba shares plunge as cannabis-based treatment fails trial. Shares of marijuana-focused biotech Zynerba surged last year among brouhaha surrounding cannabis companies seeking milestone Food and Drug Administration (FDA) approvals. But, at the end of the day, clinical trials are king—and a stunning mid-stage study failure for Zynerba's synthetic cannabis-based gel for epilepsy sent the company's shares plunging about 58% in mid-day Monday trading. Other firms like GW Pharmaceuticals are hoping for better luck as they approach their regulatory review dates.

THE BIG PICTURE

Martin Shkreli was never biopharma's black sheep. Last Friday, the infamous Martin Shkreli was convicted on three of eight criminal charges by a Brooklyn jury. This could amount to years of jail time. But it's important to note that Shkreli's alleged crimes had nothing to do with the gargantuan drug price hike which thrust him into notoriety. Drug companies are allowed to set whatever prices they want for their products under U.S. law, and certain programs meant to encourage rare disease drug development have created a market for those who would use it to reap massive financial benefits despite questionable advances for patients. For all of his bombast, Shkreli's story goes to the heart of biopharma's biggest controversies. (Fortune)

REQUIRED READING

Read Google's Response to an Employee's Controversial Diversity Memo, by Maya Rhodan

Welcome to Weedtown, USA, by David Z. Morris

Warren Buffett Is About to Hit a $100 Billion Milestone He Doesn't Want, by Bloomberg

Why Loneliness Is a Public Health Threat, by Alexandra Sifferlin

Produced by Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

Find past coverage. Sign up for other Fortune newsletters.
About the Authors
By Clifton Leaf
See full bioRight Arrow Button Icon
By Sy Mukherjee
See full bioRight Arrow Button Icon
Add Fortune on Google for similar content.

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

mitch
North AmericaCongress
Mitch McConnell, 84, hospitalized with no details released; term ends in January
By The Associated PressJune 15, 2026
9 hours ago
target
HealthRecalls
FDA recalls Nara Organics baby formula after infant botulism cases in 3 states
By The Associated PressJune 15, 2026
9 hours ago
‘There simply isn’t enough product for the U.S. customer’: GLP-1 craze eats whey too much protein
RetailFood and drink
‘There simply isn’t enough product for the U.S. customer’: GLP-1 craze eats whey too much protein
By Dee-Ann Durbin and The Associated PressJune 14, 2026
1 day ago
Middle-aged adults taking GLP-1s for obesity can save over $192K on lifetime medical costs, higher if they don’t have college degrees, new study finds
HealthHealth
Middle-aged adults taking GLP-1s for obesity can save over $192K on lifetime medical costs, higher if they don’t have college degrees, new study finds
By Mia OsmonbekovJune 14, 2026
2 days ago
U.S.’s screwworm fix is still a year away, risking more spread
North AmericaAgriculture
U.S.’s screwworm fix is still a year away, risking more spread
By Ilena Peng and BloombergJune 13, 2026
2 days ago
Meet the lone star tick: the primary U.S. source of alpha-gal syndrome, which is a life-threatening meat allergy that’s on the rise
HealthHealth
Meet the lone star tick: the primary U.S. source of alpha-gal syndrome, which is a life-threatening meat allergy that’s on the rise
By Matthew Perrone and The Associated PressJune 13, 2026
2 days ago

Most Popular

Social Security's 2032 deadline puts a 22% cut on the table — but Washington has way less room to negotiate than 1983
Personal Finance
Social Security's 2032 deadline puts a 22% cut on the table — but Washington has way less room to negotiate than 1983
By John W. Diamond and The ConversationJune 12, 2026
3 days ago
CEO of $20 billion AI firm Perplexity says the secret to success is ‘sleeping with that fear’ that your competitor will steal your idea
Success
CEO of $20 billion AI firm Perplexity says the secret to success is ‘sleeping with that fear’ that your competitor will steal your idea
By Preston ForeJune 13, 2026
3 days ago
Iran proved it can close the Strait of Hormuz, but the U.S. is advertising very loudly that the world's top superpower can at least punch open a hole
Energy
Iran proved it can close the Strait of Hormuz, but the U.S. is advertising very loudly that the world's top superpower can at least punch open a hole
By Jason MaJune 14, 2026
1 day ago
Boomers actually do hold most of the wealth and power. So why do they call it 'whiny' to point that out?
Economy
Boomers actually do hold most of the wealth and power. So why do they call it 'whiny' to point that out?
By Nick LichtenbergJune 14, 2026
1 day ago
SpaceX surge further boosts Saudi billionaire prince’s fortune
Investing
SpaceX surge further boosts Saudi billionaire prince’s fortune
By Adveith Nair and BloombergJune 14, 2026
1 day ago
AI job disruption is here. The problem may be compounded because nearly 75% of people don't apply for unemployment benefits
AI
AI job disruption is here. The problem may be compounded because nearly 75% of people don't apply for unemployment benefits
By Jacqueline MunisJune 14, 2026
1 day ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.